Thus, enhanced infiltration of CD8+ and CD4+ effector T cells in tumors and altered balance between effector T cells and regulatory T cells in favor of immunity contributed to the augmented efficacy of IL-21 and IL-7 co-expressing tumor cell vaccine. The gene discussed is CD8A; the disease is neoplasm.